Abcam, ab252547, Anti-YTHDF1 antibody [EPR22349-16] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal YTHDF1 antibody. Carrier free. Suitable for IHC-P, WB, Flow Cyt (Intra) and reacts with Rat, Mouse samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR22349-16,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Mouse, Rat,
Applications:Flow Cyt (Intra), IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab252547 is the carrier-free version of
ab252346
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
YTHDF1 also known as YTH domain family protein 1 is a reader protein of N6-methyladenosine (m6A) a common RNA modification. Its mass is approximately 64 kDa. YTHDF1 binds to m6A-modified mRNA and enhances its translation efficiency by recruiting ribosomes. This protein is present in various tissues showing higher expression in brain spleen and lymphoid tissues suggesting a role in development and immunity.
Biological function summary
YTHDF1 affects mRNA stability and translation providing a mechanism for regulating protein synthesis. It operates as part of a complex with other m6A readers like YTHDF2 and YTHDF3 which determine mRNA fate. By promoting translation YTHDF1 impacts cellular responses and adaptation to environmental changes especially during stress and division.
Pathways
YTHDF1 integrates into the mRNA surveillance pathway and translation regulation. It interacts closely with other components such as eukaryotic initiation factors (eIFs) to modulate protein synthesis dynamics. This allows cells to rapidly adjust protein levels in response to cues and maintain homeostasis. Its role is critical in link to ribosomal function and stability of gene expression networks.
YTHDF1 has connections to cancer and neurological disorders. In cancer abnormal YTHDF1 expression associates with tumor progression and metastasis and interacts with proteins like METTL3 involved in m6A deposition. In neurological disorders dysregulation of YTHDF1 influences mRNA translation tied to cognitive functions possibly interacting with neurotransmitter pathways. Understanding these roles shows potential for YTHDF1 as a therapeutic target.